BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21845514)

  • 1. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
    Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
    Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
    Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
    Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
    BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
    Kang BW; Jeong JY; Chae YS; Lee SJ; Lee YJ; Choi JY; Lee IK; Jeon SW; Bae HI; Lee DK; Kwon OK; Chung HY; Yu W; Kim JG
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):735-41. PubMed ID: 22955258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
    Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY
    Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.
    Matsuda S; Takahashi T; Fukada J; Fukuda K; Kawakubo H; Saikawa Y; Kawaguchi O; Takeuchi H; Shigematsu N; Kitagawa Y
    Radiat Oncol; 2014 Jan; 9():9. PubMed ID: 24398302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
    Kodera Y; Ishiyama A; Yoshikawa T; Kinoshita T; Ito S; Yokoyama H; Mochizuki Y; Ito H; Tsuburaya A; Sakamoto J; Nakao A;
    Gastric Cancer; 2010 Aug; 13(3):197-203. PubMed ID: 20820990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
    Kunisaki C; Ono HA; Hasegawa S; Oshima T; Fujii S; Tokuhisa M; Izumisawa Y; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    J Chemother; 2012 Dec; 24(6):364-8. PubMed ID: 23174102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer.
    Tsuchida K; Sato T; Aoyama T; Atsumi Y; Kano K; Maezawa Y; Kazama K; Numata M; Yamada T; Tamagawa H; Murakami H; Oshima T; Saeki H; Cho H; Yukawa N; Yamamoto Y; Masuda M; Rino Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):371-378. PubMed ID: 33283236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
    J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
    Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer.
    Choi IS; Lee KW; Kim KH; Kim YJ; Kim JH; Lee JS
    Med Oncol; 2010 Sep; 27(3):992-7. PubMed ID: 20077040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
    Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
    Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.